Article metrics
PDF
Other content recommended for you
- Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas
- What is CAR T-cell therapy?
- Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2
- SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report
- Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1
- CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome
- Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma
- Experiences and perspectives on chimeric antigen receptor (CAR) T-cell therapy among recipients, carers and referrers (RE-TELL): a qualitative study to inform CAR T-cell service design
- Cardiotoxicities of novel cancer immunotherapies
- CARs are sharpening their weapons